In recent news, the Bio-Techne Corporation (TECH) has been attracting investors' attention due to diverse factors. The corporation has seen a decrease due to increased investor concerns and a general weakness in research spending. However, it also received a new buy rating from TD Cowen, thereby stirring market interest. The corporation's performance has been negatively impacted because of significant funding cuts from NIH, affecting the academic research market.
Bio-Techne has also been actively forming strategic partnerships, such as with Spear Bio, to advance therapeutic development through ultrasensitive biomarker detection. They also reported strong organic growth in their Q3 2025 earnings, yet investor confidence seems shaken due to the uncertain funding environment. Recently, ScaleReady awarded multiple G-Rex® Grants to the University of Minnesota's Center for Genome Engineering.
The companies stock price has faced fluctuations due to these events, with both bullish and bearish sentiments on the street. They will be hosting an earnings call on August 6, 2025, which has been anticipated by the market. The firm's Simple Western™ Technology was recently utilized for the FDA approval of ZEVASKYN™, a cell-based gene therapy. The company has reported solid financial footing despite macroeconomic uncertainty.
Bio-Techne Corp TECH News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Fri, 01 Aug 2025 12:35:14 GMT -
